EW
Edwards Lifesciences Corporation
NYQ
$85.11
-0.65
(-0.76%)
Neutral · -0.06σ
Price chart
Overlay:
Click earnings ▲ markers for day-move details
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.6B | $0.4B | $0.5B | $-0.0B | 23.1% | 31.2% |
| 2025-12-31 | $1.6B | $0.1B | $0.4B | $0.4B | 5.8% | 23.6% |
| 2025-09-30 | $1.6B | $0.3B | $0.4B | $0.5B | 18.7% | 27.4% |
| 2025-06-30 | $1.5B | $0.3B | $0.4B | $0.2B | 21.5% | 28.1% |
| 2025-03-31 | $1.4B | $0.4B | $0.4B | $0.2B | 25.3% | 29.0% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
| 2024-09-30 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-04-23 | 0.78 | 0.73 | +7.3% |
| 2026-02-10 | 0.58 | 0.62 | -6.3% |
| 2025-10-30 | 0.67 | 0.59 | +12.6% |
| 2025-07-24 | 0.67 | 0.62 | +7.6% |
| 2025-04-23 | 0.64 | 0.60 | +7.5% |
| 2025-02-11 | 0.59 | 0.55 | +6.4% |
| 2024-10-24 | 5.13 | 0.54 | +855.0% |
| 2024-07-24 | 0.70 | 0.69 | +0.9% |
| 2024-04-25 | 0.66 | 0.64 | +2.8% |
| 2024-02-06 | 0.64 | 0.64 | +0.2% |
| 2023-10-25 | 0.59 | 0.59 | -0.7% |
| 2023-07-26 | 0.66 | 0.65 | +1.9% |
| 2023-04-26 | 0.62 | 0.61 | +2.0% |
| 2023-01-31 | 0.64 | 0.61 | +4.5% |
| 2022-10-27 | 0.61 | 0.62 | -2.0% |
| 2022-07-28 | 0.63 | 0.64 | -1.4% |
| 2022-04-26 | 0.60 | 0.57 | +5.2% |
| 2022-01-26 | 0.51 | 0.55 | -6.8% |
| 2021-10-27 | 0.54 | 0.53 | +1.7% |
| 2021-07-29 | 0.64 | 0.55 | +15.6% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| EW ★ | $49B | 46.0 | 25.3 | 7.8 | 24.2 | 4.8 | 77.9% | 16.7% | 8.2% | 1.84% |
| LLY | $1,010B | 40.3 | 25.5 | 14.0 | 28.9 | 32.4 | 82.8% | 55.5% | 169.9% | 0.91% |
| UNH | $371B | 30.8 | 19.5 | 0.8 | 19.8 | 3.8 | 18.8% | 2.0% | 0.7% | 4.77% |
| JNJ | $580B | 27.9 | 18.9 | 6.0 | 17.9 | 7.1 | 68.0% | 9.9% | -52.9% | 2.16% |
| MRK | $294B | 33.5 | 12.4 | 4.5 | 11.4 | 6.4 | 76.7% | 4.9% | — | 4.78% |
| ABBV | $402B | 111.1 | 14.0 | 6.4 | 15.6 | -60.5 | 72.0% | 12.4% | -46.2% | 5.17% |
| PFE | $149B | 20.0 | 9.3 | 2.4 | 7.9 | 1.7 | 74.8% | 5.4% | -10.1% | 8.29% |
| TMO | $174B | 25.8 | 17.2 | 3.9 | 19.0 | 3.3 | 40.9% | 6.2% | 11.3% | 3.17% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 42.42%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 52,590,933 | 9.13% |
| Vanguard Capital Management LLC | 37,727,792 | 6.55% |
| Vanguard Portfolio Management LLC | 26,407,018 | 4.59% |
| State Street Corporation | 26,296,399 | 4.57% |
| Wellington Management Group, LLP | 22,011,101 | 3.82% |
| JPMORGAN CHASE & CO | 21,744,712 | 3.78% |
| Bank Of New York Mellon Corporation | 16,737,548 | 2.91% |
| FMR, LLC | 14,503,770 | 2.52% |
| Geode Capital Management, LLC | 13,133,777 | 2.28% |
| Jennison Associates LLC | 13,066,274 | 2.27% |
Insider activity · 90d
0 buys / 8 sells · ratio 0.0 · Finnhub
- Dahl Andrew M. SELL 15,334 @ $86.08
- BOBO DONALD E JR SELL 98,611 @ $86.42
- Chopra Daveen SELL 44,324 @ $84.60
- Lippis Daniel J. M 6,190
- Lippis Daniel J. SELL 40,411 @ $81.14
- Lippis Daniel J. M 41,031 @ $72.68
- BOBO DONALD E JR SELL 30,970 @ $81.82
- BOBO DONALD E JR SELL 22,798 @ $82.07
- Zovighian Bernard J SELL 12,040 @ $77.92
- Zovighian Bernard J SELL 47,546 @ $78.40
Analyst estimates
FinnhubLow
$84.0
Mean
$96.92308
High
$110.0
Analysts
26
Recommendation distribution · period 2026-06-01
12
19
11
Revision trend (2026-03-01 → 2026-06-01):
net 31 → 31
0
(net = strong_buy+buy − sell−strong_sell)
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-05-29 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-22 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-18 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-18 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-12 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-08 | Insider transaction (Form 4) | view · |
| 8-K | 2026-05-08 | 8-K | view · |
| 10-Q | 2026-05-06 | 10-Q | view · |
| 4 | 2026-05-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-05 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-04 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-04 | Insider transaction (Form 4) | view · |
| 4 | 2026-05-04 | Insider transaction (Form 4) | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 8-K | 2026-04-23 | 8-K | view · |
| 4 | 2026-04-09 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-06 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-02 | Insider transaction (Form 4) | view · |
| DEF 14A | 2026-03-26 | DEF 14A | view · |
| 4 | 2026-03-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-11 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-02 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-26 | Insider transaction (Form 4) | view · |
| 10-K | 2026-02-25 | 10-K | view · |
| 4 | 2026-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-17 | Insider transaction (Form 4) | view · |
| 4 | 2026-02-13 | Insider transaction (Form 4) | view · |
| 8-K | 2026-02-10 | 8-K | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-09 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-06 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-12 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-12 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-12 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-10 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-10 | Insider transaction (Form 4) | view · |
| 4 | 2025-12-09 | Insider transaction (Form 4) | view · |
About
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.